Pharmacoeconomic review report : Mifepristone and misoprostol (Mifegymiso)

Pharmacoeconomic review report Mifepristone and misoprostol (Mifegymiso)

Mifepristone and misoprostol (Mifegymiso) is a combination drug product comprising a progesterone receptor antagonist and a synthetic analogue of prostaglandin E1. It is approved by Health Canada for the medical termination of a developing intrauterine pregnancy with a gestational age up to 49 days....

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health 2017.
Materias:
Drugs > Cost effectiveness.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820269206719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Information on the Pharmacoeconomic Submission
  • 1. Summary of the Manufacturer's Pharmacoeconomic Submission
  • 2. Manufacturer's Base Case
  • 3. Summary of Manufacturer's Sensitivity Analyses
  • 4. Limitations of Manufacturer's Submission
  • 5. CADTH Common Drug Review Reanalyses
  • 6. Issues for Consideration
  • 7. Patient Input
  • 8. Conclusions
  • APPENDIX 1. Cost Comparison
  • APPENDIX 2. Additional Information
  • APPENDIX 3. Summary of Other Health Technology Assessments of Drug
  • APPENDIX 4. Reviewer Worksheets
  • References.

Ejemplares similares